|
| Press Releases |
|
 |
|
| Thursday, April 24, 2025 |
|
|
HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress 2025 |
| HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, announced today that it will present at the EASL Congress 2025, taking place from May 7-10, 2025 in Amsterdam. more info >> |
|
| Tuesday, April 15, 2025 |
|
|
Berberine Ursodeoxycholate (HTD1801) Consistently Demonstrates Comprehensive Benefits for Patients with Type 2 Diabetes Mellitus, Approaching NDA |
| HighTide Therapeutics, Inc. (2511.HK), a clinical-stage biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for chronic liver and metabolic diseases, today announced that two Phase 3 trials (SYMPHONY 1 and SYMPHONY 2) of berberine ursodeoxycholate (HTD1801) in Chinese patients with type 2 diabetes mellitus (T2DM) met their primary endpoints and gated secondary endpoints. more info >> |
|
| Tuesday, March 4, 2025 |
|
|
HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open |
| HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, today announced that data from the Phase 2 proof-of-concept study evaluating berberine ursodeoxycholate (HTD1801) for the treatment of type 2 diabetes mellitus (T2DM) was published online in JAMA Network Open. more info >> |
|
| Friday, October 25, 2024 |
|
|
HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD's The Liver Meeting 2024 |
| HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, will present at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting, taking place from November 15-19, 2024 in San Diego, California. more info >> |
|
| Wednesday, September 11, 2024 |
|
|
EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies, Highlighting Benefits of Berberine Ursodeoxycholate (HTD1801) |
| HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, presents at the 60th European Association for the Study of Diabetes (EASD) Annual Meeting, taking place from September 10-13, 2024 in Madrid, Spain. more info >> |
|
| Friday, June 21, 2024 |
|
|
HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA Scientific Sessions, Highlighting Glycemic and Cardiometabolic Benefits of Berberine Ursodeoxycholate (HTD1801) |
| HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced today that it will present at the American Diabetes Association's (ADA) 84th Scientific Sessions, taking place from June 21-24, 2024 in Orlando, Florida. more info >> |
|
| Wednesday, June 5, 2024 |
|
|
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801) |
| HighTide Therapeutics, Inc. (HKEX: 2511), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced that it will make multiple presentations at the European Association for the Study of the Liver (EASL) Congress, taking place from June 5-8, 2024 in Milan, Italy. more info >> |
|
| Wednesday, January 11, 2023 |
|
|
HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study) |
| HighTide Therapeutics Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the dosing of the first patient in a Phase 2b clinical study evaluating HTD1801 for the treatment of nonalcoholic steatohepatitis ("NASH"). more info >> |
|
| Thursday, January 5, 2023 |
|
|
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations |
| HighTide Therapeutics Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases more info >> |
|
| Thursday, November 17, 2022 |
|
|
AJG Publishes Data from HighTide Therapeutics' Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis |
| HighTide Therapeutics, Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the publication of the results of their Phase 2 study of HTD1801 in adults with primary sclerosing cholangitis (PSC) in the American Journal of Gastroenterology. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Galaxy Payroll Group Limited Announces Share Consolidation
Sept 4, 2025 04:30 HKT/SGT
|
|
|
Honda Premieres a New Color Option for Four Large-size Outboard Motors at HISWA In-Water Boat Show 2025 in the Netherlands
Sept 3, 2025 23:50 JST
|
|
|
Toyota Joins TOKYO H2 Project Aiming to Make Tokyo a Global Leader in Hydrogen
Sept 3, 2025 22:39 JST
|
|
|
CENTRESTAGE celebrates a decade of style, Four days of fashion events open to all with fashion gurus leading inspiring sessions
Sept 3, 2025 20:45 HKT/SGT
|
|
|
SERES Posts Robust H1 2025 Results: Revenue Hits CNY 62.4 Billion, Net Profit Up 81% to CNY 2.94 Billion, R&D Investment Soars nearly 155% 
Sept 3, 2025 16:43 HKT/SGT
|
|
|
Sichuan Neautus TCM Files for Hong Kong IPO to Accelerate Domestic and Global Expansion
Sept 3, 2025 16:33 HKT/SGT
|
|
|
Focus Graphite Pilot Run Demonstrates Significant Increase in Large and Jumbo Flake Recovery at Lac Knife
Sept 3, 2025 11:36 HKT/SGT
|
|
|
Honda Running Team Member, Nagiya Mori, Selected to Represent Japan in World Athletics Championships Tokyo 25 (WCH Tokyo 25) Men's 5000m Event
Sept 3, 2025 12:30 JST
|
|
|
EdgePoint Launches Two More Digital Classrooms in East Malaysia under Its Connectivity for Communities Program
Sept 3, 2025 11:05 HKT/SGT
|
|
|
PCG Launches AbbyPay, a POS-Free Digital Payment Solution
Sept 3, 2025 10:43 HKT/SGT
|
|
|
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Sept 3, 2025 11:32 JST
|
|
|
Anime Tokyo Station: TV Anime "SPY x FAMILY" Special Exhibition, Period: August 16 - November 9, 2025
Sept 3, 2025 11:00 JST
|
|
|
Fujitsu, 1Finity and Arrcus sign strategic partnership agreement to deliver innovative network solutions for AI infrastructure
Sept 3, 2025 10:58 JST
|
|
|
Watch & Clock Fair and Salon de TIME open today, Showcasing World-renowned timepieces and highlighting Hong Kong's advantages as an international platform
Sept 2, 2025 19:44 HKT/SGT
|
|
|
CENTRESTAGE ELITES unveils Guo Pei's Hong Kong solo couture debut, Star-studded runway show highlights 30+ unique creations
Sept 2, 2025 18:03 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
